ZYDUS LIFESCIENCES: CO. ANNOUNCES POSITIVE TOPLINE RESULTS FROM COMPLETED EVIDENCES-X PHASE II(B) CLINICAL TRIAL OF SAROGLITAZAR MG IN MASH; TRIAL ACHIEVED PRIMARY ENDPOINT OF RESOLUTION OF STEATOHEPATITIS WITH NO WORSENING OF FIBROSIS.
August 31, 2026 1.1K
